SBGL Sibanye Gold Ltd. gains 15% Dec 20, 2019

Sibanye Gold Limited owns and operates underground and surface gold operations in South Africa. The company holds interests in the Driefontein Operations covering an area of approximately 8,561 hectares; the Kloof Operations covering an area of approximately 20,100 hectares; and the Cooke Operations located in the West Witwatersrand region, as well as in the Beatrix Operations covering an area of approximately 16,821 hectares in the Free State province of South Africa. As of December 31, 2015, it had proved and probable gold reserves of approximately 30.988Moz; and probable uranium reserves of approximately 113.8Mlb. The company also owns and operates platinum mines in South Africa. Sibanye Gold Limited was incorporated in 2002 and is based in Westonaria, South Africa.http://www.priceseries.com/trade/SBGL-Sibanye-Gold-Ltd-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019112920191220.html

RYI Ryerson Holding Corp. gains 20% Dec 20, 2019

Ryerson Holding Corporation, together with its subsidiaries, processes and distributes industrial metals in the United States, Mexico, Canada, China, and Brazil. The company offers a line of stainless steel, aluminum, carbon steel, and alloy steels, as well as nickel and red metals in various shapes and forms, including coils, sheets, rounds, hexagons, square and flat bars, plates, structural products, and tubes. It also provides value-added processing and fabrication services ranging from sawing, slitting, blanking, cutting to length, leveling, flame cutting, laser cutting, edge trimming, edge rolling, roll forming, tube manufacturing, polishing, shearing, forming, stamping, punching, and rolling shell plate to radius and beveling; and processing materials. The company serves various industries, such as commercial ground transportation manufacturing, metal fabrication and machine shops, industrial machinery and equipment manufacturing, consumer durables production, HVAC manufacturing, construction equipment manufacturing, food processing and agriculture equipment manufacturing, and oil and gas. Ryerson Holding Corporation was founded in 1842 and is headquartered in Chicago, Illinois.http://www.priceseries.com/trade/RYI-Ryerson-Holding-Corp-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2019112520191220.html

IEC IEC Electronics Corp. gains 30% Dec 20, 2019

IEC Electronics Corp., together with its subsidiaries, provides electronic contract manufacturing services in the United States. It specializes in delivering technical solutions for the custom manufacturing, product configuration, and verification testing of complex products that require a sophisticated level of manufacturing. The company manufactures a range of assemblies that are incorporated into various products, such as aerospace and defense systems, medical devices, industrial equipment, and transportation products. It serves aerospace, medical, industrial, and defense sectors through a direct sales force, as well as through a network of manufacturer's representatives. The company was founded in 1966 and is headquartered in Newark, New York.http://www.priceseries.com/trade/IEC-IEC-Electronics-Corp-stock-gains-30-percent-a-Trade-Record-by-priceSeries-2019110720191220.html

AKBA Akebia Therapeutics, Inc. gains 47% Dec 20, 2019

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.http://www.priceseries.com/trade/AKBA-Akebia-Therapeutics-Inc-stock-gains-47-percent-a-Trade-Record-by-priceSeries-2019112220191220.html

SNDX Syndax Pharmaceuticals, Inc. gains 15% Dec 18, 2019

Developing a therapy that enhances checkpoint immuno-oncology drugs.http://www.priceseries.com/trade/SNDX-Syndax-Pharmaceuticals-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019120420191218.html

GBT GLOBAL BLOOD THERAPEUTICS, INC. gains 52% Dec 18, 2019

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease (SCD) in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. The company is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California.http://www.priceseries.com/trade/GBT-GLOBAL-BLOOD-THERAPEUTICS-INC-stock-gains-52-percent-a-Trade-Record-by-priceSeries-2019111220191218.html

FGEN FibroGen, Inc gains 23% Dec 18, 2019

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.http://www.priceseries.com/trade/FGEN-FibroGen-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2019111920191218.html

CTIC CTI BioPharma Corp. gains 21% Dec 18, 2019

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.http://www.priceseries.com/trade/CTIC-CTI-BioPharma-Corp-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019121020191218.html

CLRB Cellectar Biosciences, Inc. gains 32% Dec 18, 2019

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.http://www.priceseries.com/trade/CLRB-Cellectar-Biosciences-Inc-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2019112220191218.html

PCG Pacific Gas & Electric Co. gains 36% Dec 16, 2019

PG&E Corporation, through its subsidiary, Pacific Gas and Electric Company, transmits, delivers, and sells electricity and natural gas to residential, commercial, industrial, and agricultural customers primarily in northern and central California. The company's electricity distribution network consists of approximately 142,000 circuit miles of distribution lines, 59 transmission switching substations, and 606 distribution substations; and electricity transmission network comprises approximately 18,400 circuit miles of interconnected transmission lines and 92 electric transmission substations. Its natural gas system consists of approximately 42,800 miles of distribution pipelines, approximately 6,700 miles of backbone and local transmission pipelines, and various storage facilities. The company operates various electricity generation facilities, such as nuclear, hydroelectric, fossil fuel-fired, and photovoltaic. PG&E Corporation was founded in 1905 and is headquartered in San Francisco, California.http://www.priceseries.com/trade/PCG-Pacific-Gas-&-Electric-Co-stock-gains-36-percent-a-Trade-Record-by-priceSeries-2019112920191216.html